Sangamo Therapeutics

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Retrieved on: 
Friday, March 22, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, AAV, Sangamo Therapeutics, Form, Telephone, Sale, Attention, Security (finance), Prospectus, Form S-3, Capital market, Cantor, Broadridge Financial Solutions, Therapy, Barclays

The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules.

Key Points: 
  • The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules.
  • The combined offering price of each pre-funded warrant and accompanying warrant is $0.83.
  • The gross proceeds to Sangamo from the offering, before deducting the placement agents’ fees and other offering expenses, are expected to be approximately $24.0 million.
  • The offering is expected to close on or about March 26, 2024, subject to customary closing conditions.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STAC, Gene, Orphan drug, ALTA, Haemophilia A, BBB, Patient, Health care, Quality of life, IND, Male, ERT, Investment, Therapy, Fabry disease, Plasma, Kite, Gene expression, Partnership, Central nervous system, Novartis, CNS, Pivotal, EMA, Prion, STAAR, Enzyme replacement therapy, Biogen, Tauopathy, Workforce, BLA, AAV, Sanofi, Research, DRG, Neuron, Hematology, FDA, DSM-IV codes, Brain, Sangamo Therapeutics, MAA, Haemophilia, CTA, Mouse, Female, Traffic barrier, Sodium, MHRA, Excipient, Society, Spinal cord, Toxicology, Sigma-Aldrich, Liver, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
  • “In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company,” said Sandy Macrae, Chief Executive Officer of Sangamo.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.
  • Revenues for the fourth quarter ended December 31, 2023 were $2.0 million, compared to $27.2 million for the same period in 2022.

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Retrieved on: 
Wednesday, March 13, 2024
Research, Neurology, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, STAC, AAV, Sangamo Therapeutics, Gene, Brain, Capsid, Gene expression, ALS, BBB, Central nervous system, Novartis, CNS, CTA, DRG, Traffic barrier, Prion, NHP, Tropism, IND, Nav1.7, Neuron, Biogen, Tauopathy, Excipient, Therapy, DSM-IV codes, Spinal cord, Liver, Animal, Vaccine

Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.

Key Points: 
  • Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.
  • In NHP studies when administered intravenously at clinically relevant doses, STAC-BBB demonstrated its potential to be a leading neurotropic capsid.
  • Exhibited 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published neurotropic capsid variants evaluated in the study.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Research, Sports, Pharmaceutical, Genetics, Clinical Trials, Science, Biotechnology, Neurology, Sailing, FDA, Health, Sangamo Therapeutics, Therapy

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024.
  • The Company will hold a conference call at 4:30 p.m. Eastern on Wednesday, March 13, which will be open to the public.
  • During the conference call, the company will review its financial results and provide business updates.
  • The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, March 12, 2024
CONNECT, Internal medicine, University, Growth, Biotechnology, Novo Nordisk, Hematology, Science, AML, Monroe Dunaway Anderson, Executive, Patient, SAN, Novartis, FLT3, Head, Drug, Therapy, Drug development, Sangamo Therapeutics, Molecular Partners, MorphoSys, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D.
  • as Executive Vice President and Chief Medical Officer.
  • Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology.
  • Prior to joining Rigel, Dr. Rojkjaer held several leadership positions in clinical development and medical affairs at biotechnology and global pharmaceutical companies, having most recently served as Chief Medical Officer of Sangamo Therapeutics.

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

Retrieved on: 
Monday, February 12, 2024
Research, FDA, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Fabry disease, EMA, Orphan drug, Type D, Investment, Female, ERT, BLA, STAAR, Therapy, PRIME, Sangamo Therapeutics, Patient, Male, Enzyme replacement therapy, Partnership, Pharmaceutical industry

The proposed study would enroll up to 25 patients, both male and female, without the need for a control arm.

Key Points: 
  • The proposed study would enroll up to 25 patients, both male and female, without the need for a control arm.
  • A head-to-head comparison with Enzyme Replacement Therapy (ERT) is not part of the proposed study design deemed acceptable by the FDA.
  • This approach enables a potentially more rapid, efficient and cost-effective pathway to BLA submission than originally anticipated.
  • Sangamo is deferring additional investments in planning for a registrational trial until a collaboration partnership is secured.

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Retrieved on: 
Monday, February 5, 2024
Pharmaceutical, Genetics, Health, Clinical Trials, Partnership, COVID-19, Steroid, Trial of the century, ERT, LFT, Pharmacology, Patient, Safety, FDA, Antibody, Glomerular filtration rate, Investment, Common, Fatigue, Fabry disease, Neutralizing antibody, Physical, STAAR, Therapy, Quality of life, Kidney, Headache, EGFR, Sangamo Therapeutics, Plasma, Form, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.
  • “Despite the availability of ERT and chaperone therapies, Fabry disease treatment is burdensome, with some patients still developing disease progression.
  • The most common adverse events were pyrexia, headache, COVID-19, fatigue and nasopharyngitis (majority Grade 1/2, with one Grade 3 pyrexia).
  • The data demonstrated supraphysiological plasma and liver α-Gal A activity in mouse models, supporting Phase 1/2 and potential Phase 3 clinical dosing.

Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments

Retrieved on: 
Wednesday, November 15, 2023
Accounting, Obesity, Manchester Metropolitan University, Safety, A1C, SAN, Magnetic resonance imaging, Epidemiology, Nutcracker, Therapy, Phenotype, Cardiology, Cirrhosis, FACC, Risk, Vertex Pharmaceuticals, Hospital, CMA, DSM-IV codes, Patient, Diabetes, Sangamo Therapeutics, Science, Pharmacokinetics, Heart failure, Syndrome, Health, Eli Lilly, Messenger, University, Public health, Massachusetts General Hospital, Body composition, Body mass index, MASH, Type 2, Human, Type 2 diabetes, Management, Pharmaceutical industry, Lilly, Chorus

CHARLOTTESVILLE, Va. and SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving metabolic health, today announced key clinical and corporate updates. The company randomized the first patient in the Phase 2b M-ACCEL trial of HU6, an investigational controlled metabolic accelerator (CMA), in obese subjects with Type 2 diabetes and at risk of metabolic dysfunction-associated steatohepatitis (MASH). Additionally, Rivus appointed Robert J. Schott, M.D., M.P.H., FACC, chief medical officer and appointed Ian F. Smith chairman of the board of directors.

Key Points: 
  • Additionally, Rivus appointed Robert J. Schott, M.D., M.P.H., FACC, chief medical officer and appointed Ian F. Smith chairman of the board of directors.
  • Approximately 280 adult patients will be randomized 2:1:2:2 into one of four treatment groups (placebo, HU6 150 mg, HU6 300 mg or HU6 450 mg) and treated for six months (26 weeks).
  • "I am delighted to be joining Rivus Pharmaceuticals, where the devoted founders and their team have made rapid progress in advancing HU6 into the clinic," said Dr. Schott.
  • "I look forward to partnering with the Rivus leadership team and other board members as we pursue the company's mission to improve human metabolic health caused by obesity.

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
CSU, Eli Lilly and Company, Trial of the century, Sangamo Therapeutics, Trustee, Onyx Pharmaceuticals, Leo Pharma, Acquisition, Connetable (Gatchina), MBA, BIO, CD117, Syndrome, Bachelor of Science in Human Biology, Rest, Growth, Biotechnology Innovation Organization, Risk, Methodist University, Partnership, Southern Methodist University, Pharmacy, Chairperson, Pleasure, University, Eli Lilly, Therapy, Patient, Management, Jasper, Science, Pardes

Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.

Key Points: 
  • Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.
  • “We are pleased to welcome Tom to our Board as Chairperson.
  • “I will be supporting Tom, Ron, and the rest of Jasper as I transition off the Jasper Board to new company ventures.”
    Mr. Wiggans most recently served as Chairman and CEO of Pardes Biosciences.
  • He began his career with Eli Lilly & Co. Mr. Wiggans is currently on the Board of Directors of Annexon, Inc., and Cymabay Therapeutics Inc.

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Regenerative Medicine Advanced Therapy, Ethics, Therapy, Pfizer, Gene, Partnership, Head, Exposition, European Society of Gene and Cell Therapy, ALTA, AAV, Haemophilia, Hope, 65th Street Yard, Workforce, ERT, DSM-IV codes, Cell, CAR, U.S. FDA, Safety, Investment, Patient, Central nervous system, Nav1.7, MAA, 22q13 deletion syndrome, Conference, Enzyme replacement therapy, Hematology, Quality of life, Mace Head Atmospheric Research Station, Novartis, Brain, European Society for Primary Immunodeficiencies, Haemophilia A, Spectrum, FDA, IND, Fabry disease, Prion, Society, Senior, SCN2A, ESGCT, STAAR, Intellectual disability, Sclerosis, BLA, Pharmaceutical industry, Management, Vaccine, Biogen, Neuroscience, Fabry, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.
  • As a result of this restructuring, Sangamo is reducing its US workforce by approximately 40%, or approximately 162 roles.
  • Sangamo expects to incur approximately $8 million-$10 million in one-time restructuring costs in the fourth quarter of 2023.
  • Revenues for the third quarter ended September 30, 2023 were $9.4 million, compared to $26.5 million for the same period in 2022.